Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN): $32.46

-0.04 (-0.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYGN POWR Grades


  • MYGN scores best on the Value dimension, with a Value rank ahead of 68.45% of US stocks.
  • The strongest trend for MYGN is in Momentum, which has been heading down over the past 52 weeks.
  • MYGN ranks lowest in Momentum; there it ranks in the 10th percentile.

MYGN Stock Summary

  • The ratio of debt to operating expenses for Myriad Genetics Inc is higher than it is for about merely 24.1% of US stocks.
  • MYGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 26.02% of US stocks.
  • With a year-over-year growth in debt of -31.92%, Myriad Genetics Inc's debt growth rate surpasses merely 16.45% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be CCF, PMD, OFIX, SSD, and LNN.
  • MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to myriad.com.

MYGN Valuation Summary

  • MYGN's price/sales ratio is 4.2; this is 10.53% higher than that of the median Healthcare stock.
  • MYGN's price/sales ratio has moved down 18.4 over the prior 243 months.
  • Over the past 243 months, MYGN's price/earnings ratio has gone up 101.3.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2021-08-31 4.2 3.1 -28.7 -21.0
MYGN 2021-08-30 4.2 3.1 -28.7 -21.1
MYGN 2021-08-27 4.2 3.1 -28.3 -20.8
MYGN 2021-08-26 4.0 2.9 -26.9 -19.8
MYGN 2021-08-25 4.1 3.0 -27.9 -20.5
MYGN 2021-08-24 4.1 3.0 -28.2 -20.6

MYGN Growth Metrics

  • Its 3 year price growth rate is now at -20.45%.
  • Its 3 year net income to common stockholders growth rate is now at -85.86%.
  • Its 5 year net income to common stockholders growth rate is now at -252.75%.
Over the past 49 months, MYGN's revenue has gone down $109,100,000.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 662.3 -6.3 -97.3
2021-03-31 566.1 28.1 -148
2020-12-31 557 -26.9 -223.7
2020-09-30 597.5 -14.4 -194.1
2020-06-30 638.6 60.7 -199.5
2020-03-31 760.8 62.2 -148.3

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYGN has a Quality Grade of C, ranking ahead of 60.73% of graded US stocks.
  • MYGN's asset turnover comes in at 0.476 -- ranking 96th of 681 Pharmaceutical Products stocks.
  • CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.476 0.705 -0.277
2021-03-31 0.404 0.685 -0.395
2020-12-31 0.390 0.680 -0.514
2020-09-30 0.407 0.698 -0.425
2020-06-30 0.424 0.709 -0.380
2020-03-31 0.493 0.737 -0.285

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.25 Average Broker Recommendation 2.11 (Hold)

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $32.46 52-week high $36.95
Prev. close $32.50 52-week low $12.22
Day low $32.26 Volume 507,500
Day high $32.90 Avg. volume 608,769
50-day MA $33.28 Dividend yield N/A
200-day MA $30.48 Market Cap 2.53B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics Names Pamela Wong as Chief Legal Officer

New legal leader brings healthcare expertise from Quest Diagnostics and experience at major global law firms New legal leader brings healthcare expertise from Quest Diagnostics and experience at major global law firms

Intrado Digital Media | October 18, 2021

Predictive Diagnostics Market (covid-19 analysis) SWOT analysis, key indicators, forecast to 2027 | Qiagen, Abbott, Genomic Health, Myriad Genetics, BioGenex

Predictive Diagnostics Market Scenario 2020-2027: The Global Predictive Diagnostics market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2027. On the basis of historical data, Predictive Diagnostics market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the []

Cheshire Media | October 11, 2021

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Figure 1: Among those who say they would not seek treatment Things that would lead a person to seek treatment for anxiety SALT LAKE CITY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment for mental health conditions and others say they won’t get help until these symptoms take a toll in their lives. Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe ov

Yahoo | October 11, 2021

Here''s Why You Should Retain Myriad Genetics (MYGN) for Now

Myriad Genetics, Inc. MYGN is well poised for growth in the coming quarters on the ongoing strong recovery in testing volumes. The companys recent launches of myRisk and RiskScore raise optimism. A strong solvency position is an added advantage. However, escalating expen

iShook Finance | October 4, 2021

Heres Why You Should Retain Myriad Genetics (MYGN) for Now

Myriad Genetics, Inc. MYGN is well poised for growth in the coming quarters on the ongoing strong recovery in testing volumes. The companys recent launches of myRisk and RiskScore raise optimism. A strong solvency position is an added advantage. However, escalating expenses and foreign exchange fluctuations do not bode well for the stock. Over the [] The post Heres Why You Should Retain Myriad Genetics (MYGN) for Now appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

FXNews24 | October 4, 2021

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -2.55%
3-mo 5.15%
6-mo 2.98%
1-year 122.18%
3-year -26.13%
5-year 66.21%
YTD 64.15%
2020 -27.38%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8199 seconds.